J
Jerrold M. Olefsky
Researcher at University of California, San Diego
Publications - 606
Citations - 83310
Jerrold M. Olefsky is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Insulin & Insulin resistance. The author has an hindex of 143, co-authored 595 publications receiving 77356 citations. Previous affiliations of Jerrold M. Olefsky include University of Colorado Boulder & University of Michigan.
Papers
More filters
Journal ArticleDOI
The effects of biosynthetic human proinsulin on carbohydrate metabolism in non-insulin-dependent diabetes mellitus.
Harry Glauber,Robert R. Henry,Penny Wallace,Bruce Hill Frank,John A Galloway,Robert M. Cohen,Jerrold M. Olefsky +6 more
TL;DR: It is concluded that subcutaneously injected proinsulin has prolonged pharmacokinetics in plasma and can normalize plasma glucose in NIDDM characterized by severe hyperglycemia and may have a role in the treatment of NID DM.
Journal ArticleDOI
G protein–coupled receptor 21 deletion improves insulin sensitivity in diet-induced obese mice
Olivia Osborn,Da Young Oh,Joanne C. McNelis,Manuel Sanchez-Alavez,Saswata Talukdar,Min Lu,Pingping Li,Lucinda Thiede,Hidetaka Morinaga,Jane J. Kim,Jan Heinrichsdorff,Sarah Nalbandian,Jachelle M. Ofrecio,Miriam Scadeng,Simon Schenk,John R. Hadcock,Tamas Bartfai,Jerrold M. Olefsky +17 more
TL;DR: It is found that the orphan GPCR Gpr21 was highly expressed in the hypothalamus and macrophages of mice and that whole-body KO of this receptor led to a robust improvement in glucose tolerance and systemic insulin sensitivity and a modest lean phenotype.
Journal ArticleDOI
Dissection of the growth versus metabolic effects of insulin and insulin-like growth factor-I in transfected cells expressing kinase-defective human insulin receptors.
TL;DR: It is reported here that insulin-like growth factor I-stimulated phosphorylation of two endogenous substrate proteins, pp220 and pp170, is also inhibited in cells expressing A/K1018 receptors, arguing that phorbol esters or H2O2 bypass the normal proximal steps in signalling insulin action.
Journal ArticleDOI
Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects.
TL;DR: Troglitazone lowers fasting and postprandial plasma glucose in type 2 diabetes by affecting both fasting HGO and peripheral insulin sensitivity, and its effects are evident 2-3 weeks after discontinuation.
Journal ArticleDOI
Expression of Dominant Negative Mutant SHPTP2 Attenuates Phosphatidylinositol 3′-Kinase Activity via Modulation of Phosphorylation of Insulin Receptor Substrate-1 (∗)
Satoshi Ugi,Hiroshi Maegawa,Atsunori Kashiwagi,Masaaki Adachi,Jerrold M. Olefsky,Ryuichi Kikkawa +5 more
TL;DR: The interaction of SHPTP2 with IRS-1 may be associated with modulation of phosphorylation levels of IRS- 1, resulting in the changes of PI 3′-kinase and mitogen-activated protein kinase activity.